News

  • Collaborative COVID-19 lockdown effort delivers major boost for vaccine innovation in Bristol 7 October 2021 Faster vaccine development could be a step closer thanks to £4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer™. Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
  • Bristol retains Strategic Partnership with the BBSRC and ranks fourth for bioscience research funding  30 September 2021 The BBSRC, one of the UK’s largest UK bioscience funders, has announced Bristol will retain its Strategic Partnership (SP) status. The decision was announced this month following BBSRC’s SP member triannual review. Bristol is one of only ten top-funded university partners with this status – which it has retained since 2012 recognising the University’s long-term record for excellence in biosciences research. 
  • Scientists develop the ‘evotype’ to help unlock the power of evolution for better engineering biology 8 June 2021 Scientists from the University of Bristol have pioneered a new approach to help biological engineers both harness and design the evolutionary potential of new biosystems. Their concept of the ‘evotype’ lays a foundation for the next generation of stable, safe and self-improving biotechnologies.
  • Bristol documentary photographer captures some of the faces behind COVID-19 research 27 April 2021 The human stories behind Bristol scientists who are playing an important role in global efforts to overcome COVID-19 have been captured in a billboard campaign by a Bristol-based photographer.
  • Festival presents unique opportunity to hear from world-leading researchers tackling today's global challenges 15 April 2021 Reaching net zero carbon dioxide emissions, eliminating hunger and poverty, tackling misinformation and vaccine hesitancy, decolonisation, and overcoming the digital divide are among key topics set to take centre stage at the inaugural University of Bristol Festival of International Research and Partnerships, which starts next week.
  • Newly launched British biotech company pioneers ground-breaking potential treatments for COVID-19 13 April 2021 A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for coronavirus.
  • How vitamins, steroids and potential antivirals might affect SARS-CoV-2 28 January 2021 Evidence is emerging that vitamin D – and possibly vitamins K and A – might help combat COVID-19. A new study from the University of Bristol published in the journal of the German Chemical Society Angewandte Chemie has shown how they – and other antiviral drugs – might work. The research indicates that these dietary supplements and compounds could bind to the viral spike protein and so might reduce SARS-CoV-2 infectivity. In contrast, cholesterol may increase infectivity, which could explain why having high cholesterol is considered a risk factor for serious disease.
  • Discovery of a druggable pocket in the SARS-CoV-2 Spike protein could stop virus in its tracks 21 September 2020 A druggable pocket in the SARS-CoV-2 Spike protein that could be used to stop the virus from infecting human cells has been discovered by an international team of scientists led by the University of Bristol. The researchers say their findings, published today [21 September] in the journal Science, are a potential 'game changer' in defeating the current pandemic and add that small molecule anti-viral drugs developed to target the pocket they discovered could help eliminate COVID-19.
  • German Ambassador visits the University 7 September 2020 Andreas Michaelis, German Ambassador to the Court of St James's, visited Bristol on Wednesday 2 September accompanied by his wife Frau Heike Michaelis, German Consul General Hans-Guenther Loeffler, and the new Honorary German Consul for Bristol Kai von Pahlen.
  • Scientists could help government achieve UK's net zero carbon target in groundbreaking £7.25 million project 29 June 2020 Chemists, biochemists and physicists at Bristol, Exeter and Sheffield have teamed up in a £7.25 million five-year project that could drive down the cost of energy production and help in the government’s net zero carbon ambitions
  • New vaccine platform used to develop COVID-19 candidates 7 April 2020 The University of Bristol and spin-out company Imophoron have announced they are ready to test COVID-19 vaccine candidates in a pre-clinical programme.
  • Technology takes a step forwards in genetic research 11 February 2020 New research brings combined computational and laboratory genome engineering a step closer following the design of smaller and smaller genomes, to advance genetic manipulation, using supercomputers by researchers at the University of Bristol.
  • Catalytic protocells get zingy 8 January 2020 Artificial cells capable of oxygen gas production and chemical signalling have been prepared using a combination of synthetic and biological catalysts through an international collaboration between the University of Bristol and the University of Padua in Italy.
  • UK scientists bring innovative vaccine technology to Vietnam 27 November 2019 World-leading vaccine scientists from the University of Bristol are working with one of Vietnam's major vaccine manufacturers, Vabiotech, to share cutting-edge knowledge that could help prevent future global outbreaks of avian flu and rabies.
  • Spin-out secures £1.1 million for ground-breaking 'supercharged' cell therapies to treat solid tumours 25 November 2019 A University of Bristol spin-out company has raised £1.1 million in funding to develop next generation cell therapies that could open new ways to treat solid tumours and improve the lives of 18 million people worldwide who are diagnosed with cancer each year.
  • Health pioneers celebrated at awards for life-changing chemistry innovations 31 October 2019 University of Bristol spin-out, Rosa Biotech, was named as one of the most exciting health chemistry innovators in Europe after winning a Royal Society of Chemistry (RSC) Emerging Technologies 2019 award for its biosensing platform that mimics the mammalian olfactory (smelling) system. Rosa was one of two innovations to win the award and a share of £80,000 prize.
  • University of Bristol spin-out raises £760,000 to commercialise biosensing technology 31 October 2019 Rosa Biotech, a new University of Bristol spin-out which developed a sensing platform capable of detecting the faint chemical signature given off by chronic diseases has raised £760,000 to commercialise its ground-breaking innovation. The artificial Intelligence (AI)-driven biosensing technology, which mimics mammals’ sense of smell, has significant potential to transform the medical diagnostics and pharmaceuticals industries.
  • Powerful new synthetic vaccines to combat epidemics 25 September 2019 A new type of vaccine that can be stored at warmer temperatures, removing the need for refrigeration, has been developed for mosquito-borne virus Chikungunya in a major advance in vaccine technology. The findings, published in Science Advances today [Wednesday 25 September], reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
  • Artificial red blood cells enable research into malaria invasion 29 August 2019 Researchers at the University of Bristol and Imperial College London have established a new model system that uses red blood cells grown in the laboratory to study how malaria parasites invade red blood cells.
  • Scientists hijack bacteria's homing ability 3 July 2019 In a world first, scientists have found a new way to direct stem cells to heart tissue. The findings, led by researchers at the University of Bristol and published in Chemical Science, could radically improve the treatment for cardiovascular disease, which causes more than a quarter of all deaths in the UK (1).
Years iterator
Edit this page